Nov 03, 2016
C&EN White Paper >>
Minimizing Risk in API & Drug Product Development
Brought to you by CordenPharma
& Manufacturing >> A Fully Integrated Supply Chain
Oct 17, 2016
As part of a long term growth strategy designed to meet increasing customer demands, CordenPharma has completed a recent key investment to strengthen development and manufacturing capabilities for API offerings across its Highly Potent & Oncology Platform
Sep 29, 2016
Today Corden BioChem GmbH
announced that, starting October 1st 2016
and going forward, the minimum pricing for any new order of 7-ACA will be $60 USD/kg
. Corden BioChem will no longer accept any orders below this base pricing.
Aug 31, 2016
CordenPharma is pleased to announce that their CordenPharma Chenôve (France)
manufacturing facility recently completed an FDA Inspection and received a successful response with no 483s reported. The last FDA Inspection took place in 2014.
Jul 25, 2016
Pharmaceutical Technology Interviews Dr. Michael Quirmbach, Vice President, Global Marketing & Sales, CordenPharma International >
A Decade of CordenPharma > From Inception to Full‑Service Provider
Jul 20, 2016
, part of Tides Europe taking place November 14 - 17, 2016 in Berlin
, Interviews Dr. Mimoun Ayoub
, Director, Peptides, Lipids, Carbohydrates & Injectables Platforms
on Peptide Vaccines.
Jul 01, 2016
CordenPharma is pleased to announce its expansion into the oligonucleotide Active Pharmaceutical Ingredient (API) development and manufacturing market in CordenPharma Colorado
(USA) to further strengthen its CDMO offering.
Jun 28, 2016
CordenPharma is pleased to announce the completion and approval of its aseptic filling line in CordenPharma Caponago
(IT) by the Italian AIFA
for clinical and commercial supply.
Jun 21, 2016
View an abstract of the poster to be given at the International Carbohydrate Symposium, July 17-20, 2016 at the New Orleans Marriott, LA >>
by Dr. Stewart Campbell, Head of Business Development & Product Management, Carbohydrates
>> Title: Protection against experimental melioidosis with a synthetic beta-manno-heptopyranose hexasaccharide glycoconjugate
May 27, 2016
CordenPharma International would like to notify customers about a warning letter received from the USFDA on May 24, 2016 in its CordenPharma Latina facility in Sermoneta, Italy. This action follows an earlier inspection of the site by the agency in May 2015. This matter is being considered throughout the organization with the utmost sense of urgency.
May 20, 2016
A Healthy Outlook
The pharmaceutical industry is booming, and global giant CordenPharma is well positioned to share in the spoils with its offering of a one-stop supply shop.
May 02, 2016
ICIG’s CordenPharma Group today announced the closing of a syndicated loan of EUR 60 Million. CordenPharma successfully closed its first syndicated loan on advantageous terms.
Apr 22, 2016
Drug Conjugation > How Technology Drives the Supply Chain
by Dr. Mimoun Ayoub
Director, Global Peptides, Lipids, Carbohydrates & Injectables Platforms, CPI
Apr 22, 2016
by Dr. Stewart Campbell
Targeted Delivery of Nucleic Acids via Carbohydrate-Protein Interactions
Head of Business Development & Product Management, Carbohydrates, CordenPharma Switzerland
Apr 13, 2016
AUSTIN, Texas & OKLAHOMA CITY
>> Caisson Biotech, LLC (Caisson)
, a leader in half-life extension and drug delivery, today announced it has established a global manufacturing partnership with CordenPharma International (CordenPharma)
, a full-service Contract Development & Manufacturing Organization (CDMO) manufacturing APIs and Drug Products through a network of cGMP facilities across Europe and the US.
Apr 07, 2016
During the DCAT Member Forum on Monday, March 14, 2016
of DCAT Week '16
at the Waldorf Astoria in New York City, Dr. Roberto Margarita
, Director, Global Antibiotics, Highly Potent & Oncology Platforms, CPI,
presented 4 CordenPharma announcements to the DCAT Community.
Apr 01, 2016
International Chemical Investors Group (ICIG) today announced the completion of its acquisition of Sandoz Industrial Products GmbH, a Frankfurt-Höchst based manufacturer of enzyme-based fermentation products and intermediates for the pharmaceutical industry, from Novartis Group. Sandoz Industrial Products GmbH will be re-named Corden BioChem GmbH and will be associated with the CordenPharma Group, the pharma platform of ICIG.
Mar 30, 2016
Click here to watch a video fo the newly expanded CordenPharma Plankstadt Highly Potent Development facility.
Mar 14, 2016
As part of a long term strategy to meet increasing customer demands, CordenPharma has completed two additional key investments to strengthen its development and manufacturing capabilities for Drug Product service offerings across its Highly Potent, Oncology and Injectables Platforms.
Mar 03, 2016
Where do you see your company's role in the pharmaceutical supply chain?
With well-structured product & service offerings organized under the umbrella of six distinctive technology platforms – Peptides/Lipids/Carbohydrates, Injectables, Antibiotics, Highly Potent, Oncology and Small Molecules - CordenPharma is well-positioned as a key CDMO supplier and partner to the pharmaceutical industry.
Feb 24, 2016
International Chemical Investors Group (ICIG) and Novartis Group have entered into an agreement under which ICIG will acquire all of the shares in Sandoz Industrial Products GmbH, a Frankfurt-Höchst based manufacturer of enzyme-based fermentation products and intermediates for the pharmaceutical industry, especially for the use in antibiotics. Closing of the transaction is anticipated to occur on 1 April 2016.
Feb 16, 2016
announces successful results from their recent 5 Day Intensive FDA Audit: no 483-observations and a No Action Indicated (NAI) status.
Feb 02, 2016
IBC interviews upcoming Tides 2016 Speaker Dr. Mimoun Ayoub, Director, Global Peptides, Lipids, Carbohydrates & Injectables Platforms,
on the role peptide vaccines play in the development of novel cancer therapies.
Jan 25, 2016
Following the acquisition of ORPEGEN Peptide Chemicals GmbH
on January 1, 2015, CordenPharma International announces that on July 1,2015, the non-GMP facility and personnel moved to a location in Frankfurt-Fechenheim now called CordenPharma Frankfurt.
Oct 30, 2015
Robbinsville, NJ, USA > October 26, 2015 – The Drug, Chemical & Associated Technology Association (DCAT) is pleased to announce that Dr. Roberto Margarita, Director, Global Antibiotics & Oncology Platforms at CordenPharma International has been elected by the membership to serve on DCAT’s Advisory Council for a three-year term beginning November 1, 2015.
Oct 07, 2015
& Robin Livingston
of CordenPharma Colorado
discuss innovative solutions to ensure containment of Highly Potent Active Pharmaceutical Ingredients (HPAPIs).
Jul 13, 2015
is pleased to announce that the Sterile Oncology Suite
in its CordenPharma Latina
(IT) manufacturing facility has received approval for Clinical Supply of Sterile Oncology Lyophilised Products
Jul 06, 2015
Dr. Roberto Margarita, Director, Global Antibiotics & Oncology Platforms, CPI - Pharmaceutical Technology Thought Leader Profile - Resistance to Antibiotics is Driving A New Product Wave With Innovative Challenges.
Jul 03, 2015
In a recent article in Manufacturing Chemist Pharma, CordenPharma Colorado
was mentioned in an update by SafeBridge Consultants
as a manufacturing organisation which continues to maintain effective performance in the recognition, evaluation and control of highly potent compounds.
Jun 09, 2015
International Chemical Investors Group (ICIG)
recently announced an agreement with INEOS
to acquire certain chlorovinyls assets being divested by INOVYN / INEOS
. This agreement, which has been reviewed in the context of the merger control process of both this transaction and the INOVYN JV, has now received approval of the European Commission
. The closing of the acquisition of the remedy business by ICIG is anticipated to be August 1, 2015
May 11, 2015
Cover Story >> Peptide Vaccines: A Promising Therapeutic Approach. Addressing the CMC Challenges > Chemica Oggi Oligo & Peptide Supplement, April 2015 > by Dr. Mimoun Ayoub, Global Director, Peptides / Lipids / Carbohydrates & Injectables Platforms, CPI.
May 09, 2015
Article >> The Expansion of the Therapeutic Applications of Peptides: Drivers & Challenges > Chimica Oggi Oligo & Peptide Supplement, April 2015 > Interview of Dr. Mimoun Ayoub, Global Director, Peptides / Lipids / Carbohydrates & Injectables Platforms, CPI.
May 08, 2015
Article >> Prospects Through Pharmaceutical Partnership > EuroAsia Industry Magazine, Issue 4/2015 > Interview by Ernesto Petroselli, Presdident, CordenPharma International.
May 08, 2015
Article >> Outsourcing Formulation & Manufacturing Development > Drug Development & Delivery, April 2015, Volume 15 > Contribution by Dr. Roberto Margarita, Global Director Antibiotics & Oncology Platforms, CPI
Mar 18, 2015
CordenPharma is the winner of the 2015 Life Science Leader CMO Leadership Industry Choice Award for Big Pharma
on March 18th at their awards ceremony in New York City.
Mar 18, 2015
, a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, announces it has appointed CordenPharma
as its manufacturing partner.
Mar 03, 2015
Effective March 5, 2015
, CordenPharma Switzerland
announces a transfer and change to the US Catalogue Product order process
for small pack Phospholipids
(1g and 10g) and Pseudoprolines
(10g and 25g).
Mar 02, 2015
, a CordenPharma facility near Brussels, Belgium, announces a successful completion of their recent FDA inspection.
Feb 19, 2015
On Wednesday March 18, 2015 CordenPharma will be recognized with 9 CMO Leadership Awards
presented by Life Science Leader
magazine. The Life Science Leader
CMO Leadership Awards are determined through industry research conducted by Nice Insight
Jan 16, 2015
On January 1, 2015 CordenPharma International acquired the assets of Orpegen Peptide Chemicals GmbH, located in Heidelberg, Germany, retaining both their experienced personnel and peptide capabilities. The newly acquired subsidiary, to be named CordenPharma Heidelberg, will provide innovative, cutting-edge process research and non-GMP development services.
Oct 27, 2014
CordenPharma Plankstadt announces today successful results from their recent 5 day intensive FDA Inspection: no 483-observations were found and no recommendations were given.
Feb 21, 2014
Effective February 1, 2014, CordenPharma Switzerland transfers their Amino Acid Building Blocks portfolio to Chemie Uetikon GmbH, based in Lahr, Germany
Jan 27, 2014
CordenPharma Colorado announces receipt of approval for the "Potent Compound Safety Certification" by SafeBridge® Consultants, Inc. for the safe handling of potent APIs and compounds of unknown toxicity and potency.
Nov 01, 2013
On October 31, 2013 CordenPharma acquired Ancora Pharmaceuticals
, located in Woburn, MA, USA. Ancora’s unique carbohydrate synthesis technology platform and chemistry research facilities perfectly complement CordenPharma’s capabilities in the manufacture and supply of high-quality complex synthetic molecules.
Sep 25, 2013
International Chemical Investors Group (ICIG) and Casella GmbH have reached an agreement in principle under which ICIG would acquire all of the shares of Allessa GmbH. Both parties have agreed not to disclose the purchase price.
Sep 03, 2013
CordenPharma Caponago was recently granted SHE Certification with an OH SAS 18001:2007 Certificate for the maintenance of their Safety Management System involving manufacturing activities and the packaging and control of injectable liquid, freeze-dried and powder products.
Aug 28, 2013
International Chemical Investors Group (ICIG) and the Solvay Group have entered into an agreement under which ICIG will acquire Peptisyntha SA, the Brussels, Belgium, based custom manufacturer of peptides for pharmaceutical use. Upon closing of the deal, expected later this fall, Peptisyntha will become a member of ICIG’s CordenPharma platform as its third site offering peptides manufacturing.
Jun 13, 2013
In an article on June 7th of The Boulder County Business Report, the city of Boulder, Colorado was cited for national recognition as an innovation hub in various informal polls.
Jun 03, 2013
ICIG announced today changes in the management of CordenPharma, its pharmaceutical contract manufacturing business.
May 06, 2013
Visit our upcoming poster Development of a Scalable Process for CNP-22,
presented by Valerie Paulsen, Principal Analytical Chemist, CordenPharma Colorado
at Tides 2013, May 12 - 15
Apr 05, 2013
In a recent issue of their e-newslettter PrepLC eNews, the R&D staff at Phenomenex interviews Dr. Brad DeHoff, Director of R&D for CordenPharma Colorado, about current and future trends of the CMO industry.
Mar 22, 2013
International Chemical Investors Group (ICIG) kicks off €50+ million investment at PPC, a company of WeylChem Group, the fine chemicals platform of ICIG, to develop membrane-based technology. PPC is located in Thann, France.
Mar 05, 2013
On Thursday, February 28th CordenPharma Colorado sponsored and sent 3 scientists to serve as jurors for the CordenPharma Colorado Regional Science Fair, which took place at on the University of Colorado campus in Boulder.
Feb 13, 2013
CordenPharma announces an expansion of manufacturing capabilities due to the recent acquisition by International Chemical Investors Group (ICIG) of Farchemia from the Tessenderlo Group, completed on December 5th, 2012.
Dec 13, 2012
CordenPharma Chenôve receives updated certificate of compliance to cGMP standards from the PDMA in Japan and the ANSM in France.
Nov 30, 2012
CordenPharma Caponago Receives Workplace Conditions Assessment (WCA) Achievement Award Enabled by Intertek.
Oct 24, 2012
Today Orifarm Generics announced that CordenPharma was elected as the Best Supplier in the Orifarm Generics' Supplier Evaluation 2012.
Oct 10, 2012
CordenPharma presents the award for the Most Effective Process Development/Scale-Up Programme at the European Outsourcing Awards on October 10th in Madrid during CPhI 2012. And the winner is....
Oct 09, 2012
Tessenderlo Group (NYSE Euronext: TESB) announced today that it has the intention to sell its pharmaceutical ingredients activities, Farchemia and Calaire Chimie, to International Chemical Investors Group (ICIG), a private industrial holding company. The sale concerns two production sites in France and Italy.
Oct 05, 2012
Today CordenPharma announced the approval of our proprietary generic drug product dossier for Paclitaxel in the reference state (Germany). With this approval CordenPharma is now open to out-licensing the generic Paclitaxel dossier with rights to register, promote and market the drug to esteemed customers in all EU territories.
Aug 09, 2012
CordenPharma will be Gold Sponsors of the Boulder Peptide Symposium, taking place September 26-28, 2012 at the St. Julien Hotel and Spa in Boulder, CO. Read the full story for Discounted Registration Information.
Jul 31, 2012
In the Boulder Daily Camera's annual list of Top 50 Largest Businesses, CordenPharma Colorado ties with Google Inc. at Number 42 ~ click here for the Daily Camera's full article
Feb 16, 2012
Based on its recent analysis of the pharmaceutical contract manufacturing market, Frost & Sullivan recognises CordenPharma with the 2011 Western Europe Frost & Sullivan Award for Product Differentiation Excellence.
Oct 06, 2011
We are pleased to announce that on September 1, 2011 International Chemical Investors Group (ICIG) acquired a former division of Roche to join their pharmaceutical platform CordenPharma International as CordenPharma Colorado.
Feb 03, 2011
Luxembourg – International Chemical Investors Group (ICIG) announced that it has entered into a purchase agreement under which an affiliate of ICIG will acquire the pharmaceutical intermediates business from Genzyme Corporation.